Home > Blog > Emergency use authorizations

Emergency Use Authorizations

Regulatory Consulting

Emergency Use Authorizations (EUA) are a mechanism that allows the U.S. FDA to facilitate the availability of medical countermeasures for chemical, biological, radiological, and nuclear (CBRN) threats, including emerging infectious diseases such as COVID-19 and pandemic influenza, during public health emergencies. Products that receive emergency health authorizations may be legally marketed and sold in the U.S. for the duration of the emergency or until authorization is revoked by FDA.   

Listen to the full episode on Veristat’s Advancing Revolutionary Therapies (ART) Podcast to learn more about the four primary criteria for an Emergency Use Authorization, navigating the U.S. regulatory environment, and the many nuances key to the success of an Emergency Use Authorization application.

Learning Points

  • Qualifications for the Emergency Use Authorization program
  • How to successfully apply for an Emergency Use Authorization
  • Data requirements for Emergency Use Authorizations
  • Converting Emergency Use Authorizations to full approvals

LISTEN TO PODCAST

1 min read

Meet Veristat at BIO-Europe Spring: March 23-25, 2026 - Lisbon, Portugal

Mar 23, 2026  Veristat Events

🔬 Connecting with the Global Biopharma Community

Veristat is pleased to attend BIO-Europe Spring, where biotech...

1 min read

Meet Veristat at PHUSE US Connect: Advancing Data-Driven Clinical Development

Mar 18, 2026  Veristat Events

🔬 Connecting with the Global Clinical Data and Biostatistics Community

Veristat is pleased to attend PHUSE US Connect...